Page 8 - Clinical Research Program News Today

/PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today...

Virtual gathering delivers the latest cancer science to the global community...

Verano to Add Cultivation and Fortify Retail Capacity in Pennsylvania April 22, 2021 07:00 ET | Source: Verano Holdings Corp. Verano Holdings Corp. Chicago, UNITED STATES Adds cultivation and production in Pennsylvania, with an active and completely built-out, state-of-the-art 62,000 sq. ft. indoor facility in the country’s fifth most populous state. Gives the Company the ability to further develop its retail footprint with equity in a permit to op...

April 22, 2021 at 7:33 am Published by NCV Newswire Verano to Add Cultivation and Fortify Retail Capacity in Pennsylvania Adds cultivation and production in Pennsylvania, with an active and completely built-out, state-of-the-art 62,000 sq. ft. indoor facility in the country’s fifth most populous state. Gives the Company the ability to further develop its retail footprint with equity in a permit to open six dispensaries, and a second cultivation and production facility. CHICAGO, Apri...

Share this article Share this article SHANGHAI, April 8, 2021 /PRNewswire/ -- Shanghai Genechem Co., Ltd. (Genechem), a discovery company dedicated to novel target discovery and development of novel therapeutics, today announced the appointment of Dr. Eric Rowinsky, President and Executive Chairman of the Board of Rgenix, Inc., and Dr. Manuel Hidalgo, Chief of Hematology and Medical Oncology at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center, to its Scientific Advis...

An estimated 20 million US women (and 10 million US men) will have an eating disorder at some point in their lives, says the National Eating Disorders Association (NEDA). While the exact cause of eating disorders is unknown, they are believed to develop out of a combination of biological, psychological, and sociocultural factors. Every eating disorder has its own set of symptoms and side effects. Here, clinicians provide a rundown of recognized eating disorders that you should know about. ...

Algernon CEO and CSO to Discuss New DMT Stroke Clinical Research Program Featured on BioPub Webcast Hosted by Dr. KSS MD, PhD Algernon Pharmaceuticals Inc.  a clinical stage pharmaceutical development company, is pleased to announce that Algernon’s CEO Christopher J. Moreau and CSO Dr. Mark Williams, will be discussing the Company’s New DMT Stroke Clinical Research Program on an upcoming BioPub webcast. The webcast will be held Wednesday February 3, 2021 hosted by Dr. KSS at Noon EST. The ...

Researchers develop patient-informed questionnaire tool for ventral hernia repair surgery patients Patient-reported outcomes have become a critical part of improving surgical care because of their ability to capture patient experiences, such as quality of life and satisfaction, that can help inform treatment. However, for patients undergoing abdominal hernia repair -- a common procedure performed on about 400,000 patients a year in the United States -- a tool to effectively and practically meas...

Algernon Pharmaceuticals Provides Year End Summary of Key Activities Algernon Pharmaceuticals Inc.  a clinical stage pharmaceutical development company, is pleased to provide a summary of the Company’s key activities this past calendar year. NP-120 Idiopathic Pulmonary Fibrosis & Chronic Cough Clinical Research Program March 30 – Submitted for ethics approval in Australia for a Phase 2 study of the Company’s re-purposed drug Ifenprodil for IPF and chronic cough. May 6 – … Algernon P...